CYTK Cytokinetics, Incorporated - Common Stock
$76,68
Preço · Ago 19, 2026
Fundamentais a partir de Ago 6, 2026
Intervalo 52 Semanas
$35–$88
78% of range
Classificação do Analista
BUY
28 analysts
Preço-Alvo
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Margem de Lucro Líquido
-891.6%
Sobre Cytokinetics, Incorporated - Common Stock Visão geral da empresa da Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Ler mais
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
CYTK Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$76.67
Capitalização de Mercado
$9.43B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Receita (TTM)
$88M
Rendimento div.
—
ROE
152.7%
Dívida/Capital
-0.4
Intervalo 52 Semanas
$35 – $88
CYTK Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$-535M
2016-12-31
→
2025-12-31
Margens
-891.6%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
CYTK
Mediana de Pares
P/E (TTM)
-11.7
28.5
P/S (TTM)
107.1
20.1
P/B
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Preço / FCF)
-17.6
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
CYTK
Mediana de Pares
Operating Margin (Margem Operacional)
-695.4%
—
Net Profit Margin (Margem de Lucro Líquido)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
CYTK
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
-0.4
—
Current Ratio (Índice de liquidez corrente)
4.5
5.0
Quick Ratio (Índice de Liquidez Seca)
0.7
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
CYTK
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
376.6%
—
Revenue CAGR 3Y (CAGR Receita 3A)
-2.4%
—
Revenue CAGR 5Y (CAGR Receita 5A)
9.5%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
CYTK
Mediana de Pares
CYTK Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
28 analistas
- Compra forte 6 21,4%
- Compra 19 67,9%
- Manter 3 10,7%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
20 analistas · 2026-08-18
Mediana
$107.50
← Abaixo de todos os alvos
$76.67
Mín
$85.00
Máx
$146.00
Alvo mediano
$107.50
+40,2%
Alvo médio
$109.90
+43,3%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.08%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 de Março de 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 de Dezembro de 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 de Setembro de 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 de Junho de 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 de Março de 2025 | $-1.39 | $-1.41 | 0.02% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Balanço Patrimonial 26
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Demonstração de Resultados 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Balanço Patrimonial 24
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Fluxo de Caixa 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Avaliação (TTM) 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $88M | $18M | $8M | $95M | $70M |
| Margem Operacional % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Lucro líquido | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Diluído | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Índice de liquidez corrente | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Índice de Liquidez Seca | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-535M | $-400M | $-416M | $-311M | $-191M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 539 declarantes · $9.0B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 104 (+7 vs trimestre anterior) | 49 (-8 vs trimestre anterior) | 222 (+45 vs trimestre anterior) | 112 (-32 vs trimestre anterior) | +17.8M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571.778.157 | 6.711.799 | 6,37% | Ações |
| STATE STREET CORP | $553.243.709 | 6.494.233 | 6,16% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $521.151.103 | 6.117.515 | 5,80% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $509.521.049 | 5.980.996 | 5,68% | Ações |
| Avoro Capital Advisors LLC | $425.949.915 | 4.999.999 | 4,74% | Ações |
| FMR LLC | $375.035.430 | 4.402.341 | 4,18% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $259.207.450 | 3.042.018 | 2,89% | Ações |
| BANK OF AMERICA CORP /DE/ | $251.706.463 | 2.954.648 | 2,80% | Ações |
| RTW INVESTMENTS, LP | $243.814.036 | 2.862.003 | 2,72% | Ações |
| Polar Capital Holdings Plc | $191.988.358 | 2.253.649 | 2,14% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161.060.214 | 1.890.600 | 1,79% | Opção de compra |
| Capital Research Global Investors | $143.683.584 | 1.686.625 | 1,60% | Ações |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136.597.224 | 1.603.442 | 1,52% | Ações |
| Integral Health Asset Management, LLC | $136.304.000 | 1.600.000 | 1,52% | Ações |
| Point72 Asset Management, L.P. | $135.257.185 | 1.587.712 | 1,51% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133.386.924 | 1.565.758 | 1,49% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131.998.327 | 1.549.458 | 1,47% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $111.435.932 | 1.308.087 | 1,24% | Ações |
| Capital International Investors | $111.245.191 | 1.305.848 | 1,24% | Ações |
| ARMISTICE CAPITAL, LLC | $106.487.500 | 1.250.000 | 1,19% | Opção de compra |
| ARMISTICE CAPITAL, LLC | $102.342.325 | 1.201.342 | 1,14% | Ações |
| Pictet Asset Management Holding SA | $99.038.455 | 1.160.463 | 1,10% | Ações |
| Frazier Life Sciences Management, L.P. | $98.810.092 | 1.159.879 | 1,10% | Ações |
| Holocene Advisors, LP | $97.506.685 | 1.144.579 | 1,09% | Ações |
| Woodline Partners LP | $93.769.315 | 1.100.708 | 1,04% | Ações |
| NORGES BANK | $86.512.319 | 1.015.522 | 0,96% | Ações |
| Royalty Pharma Sub-Manager, LLC | $83.519.594 | 980.392 | 0,93% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81.937.000 | 961.815 | 0,91% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $77.218.175 | 906.423 | 0,86% | Ações |
| CITADEL ADVISORS LLC | $77.062.874 | 904.600 | 0,86% | Opção de compra |
| Melqart Asset Management (UK) Ltd | $65.385.455 | 767.525 | 0,73% | Ações |
| Siren, L.L.C. | $64.655.121 | 758.952 | 0,72% | Ações |
| Fisher Asset Management, LLC | $63.355.547 | 743.697 | 0,71% | Ações |
| Foresite Capital Management IV, LLC | $60.884.867 | 714.695 | 0,68% | Ações |
| Balyasny Asset Management L.P. | $60.599.821 | 711.349 | 0,67% | Ações |
| Deep Track Capital, LP | $59.633.000 | 700.000 | 0,66% | Ações |
| JANE STREET GROUP, LLC | $59.633.000 | 700.000 | 0,66% | Opção de compra |
| BNP PARIBAS FINANCIAL MARKETS | $58.702.470 | 689.077 | 0,65% | Ações |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56.251.809 | 660.310 | 0,63% | Ações |
| CITADEL ADVISORS LLC | $54.601.338 | 640.936 | 0,61% | Ações |
| GOLDMAN SACHS GROUP INC | $54.053.311 | 634.503 | 0,60% | Ações |
| Qube Research & Technologies Ltd | $48.774.257 | 572.535 | 0,54% | Ações |
| EVENTIDE ASSET MANAGEMENT, LLC | $48.081.832 | 564.398 | 0,54% | Ações |
| Affinity Asset Advisors, LLC | $46.854.500 | 550.000 | 0,52% | Ações |
| First Turn Management, LLC | $44.930.228 | 527.412 | 0,50% | Ações |
| AMERICAN CENTURY COMPANIES INC | $44.162.525 | 518.398 | 0,49% | Ações |
| Caption Management, LLC | $43.651.356 | 512.400 | 0,49% | Opção de compra |
| D. E. Shaw & Co., Inc. | $40.874.247 | 479.801 | 0,46% | Ações |
| Checkpoint Capital L.P. | $40.465.250 | 475.000 | 0,45% | Ações |
| Hood River Capital Management LLC | $39.977.367 | 469.273 | 0,45% | Ações |
| RP Management, LLC | $39.401.954 | 980.392 | 0,44% | Ações |
| EMERALD ADVISERS, LLC | $39.013.272 | 457.956 | 0,43% | Ações |
| ADAR1 Capital Management, LLC | $39.009.097 | 457.907 | 0,43% | Ações |
| AMERIPRISE FINANCIAL INC | $38.010.006 | 446.179 | 0,42% | Ações |
| Candriam S.C.A. | $37.708.477 | 443.066 | 0,42% | Ações |
| MARSHALL WACE, LLP | $36.259.335 | 425.629 | 0,40% | Ações |
| RHUMBLINE ADVISERS | $35.933.015 | 421.799 | 0,40% | Ações |
| CITADEL ADVISORS LLC | $35.882.028 | 421.200 | 0,40% | Opção de venda |
| ALLIANCEBERNSTEIN L.P. | $35.327.299 | 535.993 | 0,39% | Ações |
| GILDER GAGNON HOWE & CO LLC | $34.096.829 | 400.245 | 0,38% | Ações |
| TD Asset Management Inc | $32.809.225 | 385.130 | 0,37% | Ações |
| BlackRock, Inc. | $29.124.928 | 341.882 | 0,32% | Ações |
| GSK plc | $29.001.573 | 340.434 | 0,32% | Ações |
| TWO SIGMA INVESTMENTS, LP | $27.040.243 | 317.411 | 0,30% | Ações |
| CITIGROUP INC | $26.852.314 | 315.205 | 0,30% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.671.024 | 289.600 | 0,27% | Opção de venda |
| Trails Edge Capital Partners, LP | $24.542.302 | 288.089 | 0,27% | Ações |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23.833.521 | 279.769 | 0,27% | Ações |
| Polaris Capital Management, LLC | $22.737.211 | 266.900 | 0,25% | Ações |
| SEGALL BRYANT & HAMILL, LLC | $21.899.197 | 257.063 | 0,24% | Ações |
| Alyeska Investment Group, L.P. | $21.297.500 | 250.000 | 0,24% | Ações |
| ExodusPoint Capital Management, LP | $21.234.374 | 249.259 | 0,24% | Ações |
| Capital World Investors | $21.196.550 | 248.815 | 0,24% | Ações |
| Walleye Capital LLC | $20.422.428 | 239.728 | 0,23% | Ações |
| E. Ohman J:or Asset Management AB | $19.823.223 | 300.762 | 0,22% | Ações |
| Sarissa Capital Management LP | $19.476.393 | 228.623 | 0,22% | Ações |
| Swiss National Bank | $18.946.256 | 222.400 | 0,21% | Ações |
| SPHERA FUNDS MANAGEMENT LTD. | $18.740.693 | 219.987 | 0,21% | Ações |
| BAKER BROS. ADVISORS LP | $17.997.836 | 211.267 | 0,20% | Ações |
| California Public Employees Retirement System | $17.979.520 | 211.052 | 0,20% | Ações |
| Nicholas Investment Partners, LP | $17.810.758 | 209.071 | 0,20% | Ações |
| PINNACLE ASSOCIATES LTD | $17.245.864 | 202.440 | 0,19% | Ações |
| Mirador Capital Partners LP | $17.239.900 | 202.370 | 0,19% | Ações |
| Tri Locum Partners LP | $16.526.860 | 194.000 | 0,18% | Ações |
| PFM Health Sciences, LP | $16.329.730 | 191.686 | 0,18% | Ações |
| Rock Springs Capital Management LP | $16.014.016 | 187.980 | 0,18% | Ações |
| PRUDENTIAL FINANCIAL INC | $15.933.512 | 187.035 | 0,18% | Ações |
| DAFNA Capital Management LLC | $14.652.510 | 171.998 | 0,16% | Ações |
| Ghisallo Capital Management LLC | $14.482.300 | 170.000 | 0,16% | Ações |
| Impax Asset Management Group plc | $14.056.350 | 165.000 | 0,16% | Ações |
| Lombard Odier Asset Management (Europe) Ltd | $13.494.096 | 158.400 | 0,15% | Opção de compra |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13.383.349 | 157.100 | 0,15% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13.330.276 | 156.477 | 0,15% | Ações |
| JANE STREET GROUP, LLC | $12.735.905 | 149.500 | 0,14% | Opção de venda |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12.145.719 | 139.190 | 0,14% | Ações |
| Retirement Systems of Alabama | $11.962.891 | 140.426 | 0,13% | Ações |
| MetLife Investment Management, LLC | $11.930.519 | 140.046 | 0,13% | Ações |
| Polymer Capital Management (HK) LTD | $11.777.943 | 138.255 | 0,13% | Ações |
| Cinctive Capital Management LP | $11.742.419 | 137.838 | 0,13% | Ações |
| TUDOR INVESTMENT CORP ET AL | $11.279.156 | 132.400 | 0,13% | Opção de compra |
Executivos da empresa 52 insiders · 18 diretores · 22 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 1 de Julho de 2026 M | 63.221 | 0 | 5 | $-5.695.855 |
| Ching Jaw | SVP Finance & CFO | 6 de Março de 2023 A | 87.346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 de Fevereiro de 2017 F | 40.323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 de Agosto de 2026 M | 153.902 | 0 | 22 | $-4.429.370 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 de Julho de 2026 M | 58.555 | 0 | 24 | $-15.318.893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 de Março de 2026 A | 107.943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 de Dezembro de 2024 A | 18.655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 de Agosto de 2024 A | 33.140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 de Março de 2022 M | 103.408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 de Março de 2022 F | 153.233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 de Fevereiro de 2018 A | 32.548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 de Fevereiro de 2018 A | 21.520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 de Agosto de 2017 M | 46.441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 de Fevereiro de 2017 A | 29.004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 de Fevereiro de 2017 A | 47.255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 de Fevereiro de 2011 A | 42.000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 de Dezembro de 2009 M | 20.043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 de Fevereiro de 2008 A | 47.896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Conselheiro | 15 de Julho de 2026 A | 21.932 | 0 | 2 | $-248.260 |
| James M Daly | Conselheiro | 15 de Julho de 2026 A | 3.390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Conselheiro | 15 de Julho de 2026 A | 10.434 | 0 | 6 | $-3.544.372 |
| Nancy Wysenski | Conselheiro | 15 de Julho de 2026 A | 33.992 | 0 | 0 | $0 |
| Wendell Wierenga | Conselheiro | 15 de Julho de 2026 A | 35.563 | 0 | 3 | $-1.881.925 |
| John T Henderson | Conselheiro | 15 de Julho de 2026 A | 78.360 | 0 | 2 | $-2.078.525 |
| Lynne B Parshall | Conselheiro | 1 de Junho de 2026 S | 15.784 | 0 | 3 | $-1.000.100 |
| Muna Bhanji | Conselheiro | 27 de Maio de 2026 A | 26.361 | 0 | 0 | $0 |
| Robert E Landry | Conselheiro | 27 de Maio de 2026 A | 10.184 | 0 | 0 | $0 |
| Wendall Wierenga | Conselheiro | 15 de Julho de 2025 A | 32.345 | 0 | 0 | $0 |
| COSTA SANTO J | Conselheiro | 15 de Maio de 2024 A | 20.600 | 0 | 0 | $0 |
| Sandford D Smith | Conselheiro | 2 de Janeiro de 2024 A | 18.801 | 0 | 0 | $0 |
| Robert Califf | Conselheiro | 3 de Janeiro de 2022 A | 6.003 | 0 | 0 | $0 |
| GAGE L PATRICK | Conselheiro | 8 de Novembro de 2021 M | 28.932 | 0 | 0 | $0 |
| Denise Gilbert | Conselheiro | 20 de Maio de 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Conselheiro | 2 de Janeiro de 2013 A | 1.421.052 | 0 | 0 | $0 |
| James A Spudich | Conselheiro | 18 de Maio de 2011 A | 180.600 | 0 | 0 | $0 |
| Grant A Heidrich III | Conselheiro | 3 de Janeiro de 2011 A | 93.755 | 0 | 0 | $0 |
| Michael Schmertzler | Conselheiro | 3 de Junho de 2010 S | 4.340.923 | 0 | 0 | $0 |
| Mark Mcdade | Conselheiro | 21 de Maio de 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Conselheiro | 22 de Maio de 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Conselheiro | 29 de Abril de 2004 C | 172.413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Detentor de 10% | 29 de Abril de 2004 C | 1.615.716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Detentor de 10% | 29 de Abril de 2004 C | 771.052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Detentor de 10% | 29 de Abril de 2004 C | 650.000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Detentor de 10% | 29 de Abril de 2004 C | 755.631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 de Agosto de 2026 M | 377.820 | 0 | 19 | $-9.702.097 |
| Elisabeth Schnieders | — | 28 de Fevereiro de 2017 A | 43.919 | 0 | 0 | $0 |
| James H Sabry | — | 3 de Junho de 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 de Abril de 2004 C | 24.050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 de Abril de 2004 C | 625.950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 de Abril de 2004 C | 1.742.951 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 84 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43.268 NS | 31 de Maio de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17.069 NS | 31 de Maio de 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,81% | 58.136 SH | 8 de Agosto de 2026 | Diário |
| FMED · Fidelity Covington Trust | 1,55% | 8.262 NS | 31 de Maio de 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3.663 NS | 31 de Maio de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189.801 NS | 30 de Abril de 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48.338 NS | 30 de Abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76.297 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,75% | 874.995 SH | 8 de Agosto de 2026 | Diário |
| BBC · ETFis Series Trust I | 0,75% | 4.355 NS | 30 de Abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,71% | 7.377 SH | 8 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102.933 SH | 8 de Agosto de 2026 | Diário |
| IWN · iShares Trust | 0,62% | 1.099.434 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41.612 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4.553 NS | 31 de Maio de 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94.565 NS | 30 de Abril de 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 de Maio de 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 21.543 SH | 8 de Agosto de 2026 | Diário |
| XJH · iShares Trust | 0,35% | 18.349 SH | 8 de Agosto de 2026 | Diário |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16.959 NS | 30 de Abril de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761.130 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,34% | 3.349.200 SH | 8 de Agosto de 2026 | Diário |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72.343 SH | 8 de Agosto de 2026 | Diário |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1.797.986 SH | 8 de Agosto de 2026 | Diário |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219.413 SH | 8 de Agosto de 2026 | Diário |
| IJK · iShares Trust | 0,32% | 429.311 SH | 8 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,32% | 38.968 SH | 8 de Agosto de 2026 | Diário |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53.623 SH | 8 de Agosto de 2026 | Diário |
| IJH · iShares Trust | 0,30% | 4.684.495 SH | 8 de Agosto de 2026 | Diário |
| IJJ · iShares Trust | 0,29% | 317.724 SH | 8 de Agosto de 2026 | Diário |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55.086 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6.062 NS | 31 de Maio de 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51.834 NS | 30 de Abril de 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14.028 NS | 30 de Abril de 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4.565 NS | 31 de Maio de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635.330 NS | 31 de Maio de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19.862 NS | 30 de Abril de 2026 | N-PORT |
| ESML · iShares Trust | 0,20% | 72.711 SH | 8 de Agosto de 2026 | Diário |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356.940 NS | 31 de Maio de 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37.821 NS | 30 de Abril de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40.586 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,16% | 5.525 SH | 8 de Agosto de 2026 | Diário |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2.025 NS | 30 de Abril de 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 de Maio de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11.444 NS | 30 de Abril de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47.609 NS | 30 de Abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4.765 NS | 31 de Maio de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2.868 NS | 30 de Abril de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3.113.794 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,14% | 333.056 SH | 8 de Agosto de 2026 | Diário |